LIMK1/2 的诊断和预后价值：泛癌分析。

The Diagnostic and Prognostic Value of LIMK1/2: A Pan-Cancer Analysis.

机构信息

Department of Hematology, First Affiliated Hospital, Army Medical University, Chongqing, China.

Department of Gastroenterology, First Affiliated Hospital, Army Medical University, Chongqing, China.

出版信息

Ann Clin Lab Sci. 2021 Sep;51(5):615-624.

PMID:34686503

Abstract

BACKGROUND

LIM Kinase 1/2 (LIMK1/2) is a member of a conserved gene family of serine/threonine kinases.

OBJECTIVE

This study aims to unravel the diagnostic and prognostic value of LIMK1/2 in pan-cancer.

METHODS

A total of 33 cancer types with 11,057 samples from the TCGA database were downloaded. The immune subtypes C1 to C6 of cancers were indicated by previous studies. The ESTIMATE algorithm was used to calculate the infiltrating levels of immune cells and stromal cells. Cancer stemness was computed by DNAss and RNAss. Drug response was estimated using the CellMiner database. The functional enrichment analysis was performed by the Gene Set Enrichment Analysis method.

RESULTS

LIMK1 is highly upregulated in multiple cancer tissues compared with normal tissues. LIMK2 is also significantly dysregulated in various cancer types. Abnormally expressed LIMK1 and LIMK2 can effectively predict the overall survival of different cancer patients. Further analyses were conducted to reveal the correlation between LIMK1/2 expression and immune subtype, immune scores, cancer stemness, tumor mutation burden, drug response, and functional enrichment analysis.

CONCLUSION

The results provide a comprehensive insight into LIMK1 and LIMK2 in multiple cancers and as novel therapeutic targets for cancer treatment.

摘要

背景

LIM 激酶 1/2（LIMK1/2）是丝氨酸/苏氨酸激酶保守基因家族的成员。

目的

本研究旨在揭示 LIMK1/2 在泛癌中的诊断和预后价值。

方法

从 TCGA 数据库中下载了共 33 种癌症类型的 11057 个样本。之前的研究表明，癌症的免疫亚型为 C1 至 C6。使用 ESTIMATE 算法计算免疫细胞和基质细胞的浸润水平。使用 DNAss 和 RNAss 计算癌症干性。使用 CellMiner 数据库估计药物反应。通过基因集富集分析方法进行功能富集分析。